VTGN

In November 2025, Vistagen reported its Q2 2026 earnings. In December 2025, the company's stock plunged after its PALISADE-3 Phase 3 study failed, and Vistagen announced cash preservation measures. In February 2026, Vistagen reported its Q3 2026 earnings and received a Nasdaq non-compliance notice. In March 2026, Vistagen reduced its workforce by approximately 20% and announced participation in investor conferences. In April 2026, Vistagen received FDA approval to proceed with Phase 2 clinical development for refisolone nasal spray. In May 2026, Vistagen completed the last patient visit in the PALISADE-4 Phase 3 clinical trial, with topline results expected in the second quarter of 2026. The stock price as of May 6, 2026, was $0.61 per share, a 74% decline over the past year.